Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden |
|
|
| Active, not recruiting | 2 | 98 | Europe | Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO® | Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer | Follicular Lymphoma | 09/23 | 05/26 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
